| Senju Pharmaceutical Co., Ltd. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120135947 | OIL-IN-WATER EMULSION COMPOSITION CONTAINING DIFLUPREDNATE AND TOBRAMYCIN - The present invention provides an oil-in-water emulsion composition for topical administration, containing (a) tobramycin, (b) difluprednate, (c) water, (d) oil and (e) an emulsifier. Moreover, it provides a method for stabilizing tobramycin, which includes mixing (a) tobramycin, (b) difluprednate, (c) water, (d) oil and (e) an emulsifier to form an oil-in-water emulsion. The present invention can provide an oil-in-water emulsion composition containing tobramycin, which can maintain tobramycin content stably even when a non-ionic surfactant is added. | 05-31-2012 |
| 20120022473 | RING-SHAPED DEVICE - The present invention aims to provide a ring-shaped device superior in the wearing comfort and intraocular stability while being worn on the eye. | 01-26-2012 |
| 20120016020 | SOLID DISPERSION OF ALPHA-KETOAMIDE DERIVATIVES - A solid dispersion comprising ((1S)-1-((((1S)-1-benzyl-2,3-dioxo-3-(cyclopropylamino)propyl)amino)carbonyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester made amorphous in the presence of a water-soluble cellulosic polymer has improved storage stability. The solid dispersion also has improved solubility for an improved bioavailability. | 01-19-2012 |
| 20110306661 | HYDROGEL CONTACT LENS FOR SUSTAINED DRUG RELEASE AND DRUG RELEASE METHOD USING HYDROGEL CONTACT LENS FOR SUSTAINED DRUG RELEASE - Disclosed is a sustainedly drug-releasing hydrogel contact lens which can sustainedly release an anionic medicament such as an allergy-treating agent in a mildly irritating and effective manner while achieving vision correction. Specifically disclosed is a hydrogel comprising ionic monomers composed of at least a cationic monomer and an anionic monomer, wherein the component ratio of the ionic monomers is 5 to 20 mol % inclusive relative to the total amount of monomers that constitute the gel, and the content of the anionic monomer is 15 to 25 mol % inclusive relative to the content of the cationic monomer. | 12-15-2011 |
| 20110294880 | PHARMACEUTICAL COMPOSITION CONTAINING PROSTAGLANDIN - An object of the present invention is to provide a stable aqueous pharmaceutical composition which suppresses degradation of prostaglandin F | 12-01-2011 |
| 20110213008 | PHARMACEUTICAL CONTAINING HIF-1 ALPHA AND HIF-2 ALPHA EXPRESSION INHIBITOR - Provided is a pharmaceutical product exhibiting a high therapeutic effect in the treatment of retinal diseases associated with angiogenesis such as age-related macular degeneration, diabetic retinopathy and the like. A therapeutic agent for a retinal disease, containing a substance specifically inhibiting HIF-1α expression and a substance specifically inhibiting HIF-2α expression. The aforementioned inhibitory substances, which are active ingredients in the therapeutic agent of the present invention, are nucleic acids capable of inducing RNAi, antisense nucleic acids or ribozymes for HIF-1α and HIF-2α, or expression vectors thereof. | 09-01-2011 |
| 20110105625 | OPHTHALMIC COMPOSITION FOR CONTACT LENS - Disclosed are; a method for suppressing adsorption of a refreshing agent and/or chlorobutanol by a contact lens in an aqueous ophthalmic composition for contact lens containing a refreshing agent and/or chlorobutanol, as well as for suppressing pH decline due to degradation of chlorobutanol, wherein the method comprises preparing the composition in the form of an oil-in-water type emulsion. An ophthalmic composition for contact lens in the form of an oil-in-water type emulsion containing a refreshing agent and/or chlorobutanol is also disclosed. | 05-05-2011 |
| 20110008891 | PARTIAL PEPTIDE OF LACRITIN - The invention provides a polypeptide comprising the amino acid sequence of SEQ ID NO: 1, which is a particular partial sequence of lacritin, and having an amino acid length of not more than 70 residues. The polypeptide of the invention can promote adhesion between a cell and an extracellular matrix, and can promote tear fluid secretion from lacrimal gland acinar cells. | 01-13-2011 |
| 20100233240 | CORNEAL ENDOTHELIAL PREPARATION WHICH ENABLES CELLS TO GROW IN VIVO - The present invention provides a graft more suitable for the transplantation of corneal endothelial cells and an application method thereof. Specifically, the present invention provides a corneal endothelial preparation capable of cell proliferation in vivo, which contains a substrate and a corneal endothelial cell layer cultured on the substrate, and a treatment method of a disease selected from the group consisting of bullous keratopathy, corneal edema, corneal leukoma and corneal endothelial inflammation, which includes a step of transplanting the preparation to patients. As the substrate, collagen is used. | 09-16-2010 |
| 20100209402 | AGENT FOR PROMOTING CORNEAL ENDOTHELIAL CELL ADHESION - The invention provides an agent for promoting adhesion of a corneal endothelial cell, containing a Rho kinase inhibitor, as well as a culture medium for a corneal endothelial cell, a solution for preservation of cornea, and a method of producing a corneal endothelial preparation, which includes culturing the corneal endothelial cell using the aforementioned culture medium. | 08-19-2010 |
| 20100152288 | NOVEL a-LIPOIC ACID DERIVATIVES AND APPLICATIONS THEREOF - Provided are novel α-lipoic acid derivatives represented by the following formula (I), which have a tyrosinase inhibiting activity, a melanin production suppressing activity and an elastase inhibiting activity. | 06-17-2010 |
| 20100144792 | NEURITE FORMATION PROMOTER - The invention provides an agent for promoting ocular tissue neuritogenesis, containing N-(1-acetylpiperidin-4-yl)-4-fluorobenzamide or a pharmaceutically acceptable salt thereof, and an agent for promoting corneal neuritogenesis and retinal neuritogenesis, containing N-(1-acetylpiperidin-4-yl)-4-fluorobenzamide or a pharmaceutically acceptable salt thereof. The corneal neuritogenesis promoter can be used for the improvement of corneal sensitivity, treatment of dry eye, or treatment of a corneal epithelial disorder. The retinal neuritogenesis promoter can be used for the improvement of a visual dysfunction. | 06-10-2010 |
| 20100076552 | SUSPENSION FOR VISUALIZATION OF TRANSPARENT TISSUE IN EYE - Disclosed is an ocular transparent tissue-visualizing suspension which can be used as an easy-to-handle and sufficiently safe means to enhance visibility of transparent tissues of the eye during a surgical operation on them. The ocular transparent tissue-visualizing suspension comprises, in an aqueous medium, fine particles of a biodegradable macromolecular compound and at least one salt selected from the groups consisting of salts of trivalent metals and salts of divalent metals. | 03-25-2010 |
| 20090253807 | AQUEOUS SUSPENSION PREPARATIONS - Addition of polyvinylpyrrolidone and a water-soluble anionic macromolecular compound to an aqueous suspension of a hardly soluble drug allows to provide an aqueous suspension in which aggregation of drug particles, formation of macro crystals from suspended particles and formation of secondary particles from deposited particles are prevented, and adhesion and adsorption to containers made of plastics, e.g., polypropylene or polyethylene, are avoided. As it has a good redispersibility, the aqueous suspension is useful as eye drops, nasal drops, ear drops, injections, oral preparations, liniments and lotions. | 10-08-2009 |
| 20090247752 | GATIFLOXACIN-CONTAINING AQUEOUS LIQUID PREPARATION, ITS PRODUCTION AND METHOD FOR SUPPRESSING FORMATION OF PRECIPITATE DURING STORAGE AT LOWER TEMPERATURE AND AT THE TIME OF FREEZING AND THAWING OF THE AQUEOUS LIQUID PREPARATION - There is provided an aqueous liquid preparation comprising 0.65 to 2 w/v % of Gatifloxacin or a pharmacologically acceptable salt thereof or a hydrate thereof as free Gatifloxacin, and at least 0.5 w/v % of at least one of the ingredient selected from the group consisting of phosphoric acid, malonic acid, nicotinamide and a salt thereof, wherein a pH thereof is 5.8 to 6.9. In the aqueous liquid preparation, the solubility of Gatifloxacin is increased and the formation of a precipitate during storage at a lower temperature and at the time of freezing and thawing of the aqueous liquid preparation is suppressed by incorporating at least one of the ingredient selected from the group consisting of nicotinamide, caffeine, methylglucamine and Methyl parahydroxybenzoate into the aqueous liquid preparation. | 10-01-2009 |
| 20090247543 | GATIFLOXACIN-CONTAINING AQUEOUS LIQUID PREPARATION - There is provided an aqueous liquid preparation comprising Gatifloxacin or a pharmacologically acceptable salt thereof or a hydrate thereof, phosphoric acid or a salt thereof, and xanthan gum, wherein a pH thereof is 5.5 or more and less than 7.0. The aqueous liquid preparation has improved intraocular penetration of Gatifloxacin. Further, the formation of a precipitate during storage at a lower temperature and at the time of freezing and thawing of the aqueous liquid preparation is suppressed by incorporating at least one of the ingredient selected from the group consisting of nicotinamide, caffeine, methylglucamine, methyl parahydroxybenzoate and a salt thereof into the aqueous liquid preparation. | 10-01-2009 |
| 20090220580 | Percutaneous Absorption Formulation - The present invention provides a percutaneous absorption formulation including a patch having an adhesive layer disposed on a substrate and the adhesive layer contains ketotifen fumarate and tris(hydroxymethyl)aminomethane, and the patch is packaged in a hygroscopic packaging material. In the percutaneous absorption formulation, tris(hydroxymethyl)aminomethane particularly selected from various basic substances is incorporated, and by packaging the patch in a hygroscopic packaging material, the percutaneous absorptivity and content stability of a drug can be simultaneously improved and the yellowing of the drug can be suppressed. These effects can be further improved by the incorporation of propyl gallate, the use of an adhesive layer including an SIS-based adhesive base and a rosin ester-based adhesion imparting resin, and/or the removal of oxygen from the atmosphere in the inside of the packaging material. | 09-03-2009 |
| 20090085007 | OPHTHALMIC COMPOSITION FOR CONTACT LENS - Disclosed are; a method for suppressing adsorption of a refreshing agent and/or chlorobutanol by a contact lens in an aqueous ophthalmic composition for contact lens containing a refreshing agent and/or chlorobutanol, as well as for suppressing pH decline due to degradation of chlorobutanol, wherein the method comprises preparing the composition in the form of an oil-in-water type emulsion. An ophthalmic composition for contact lens in the form of an oil-in-water type emulsion containing a refreshing agent and/or chlorobutanol is also disclosed. | 04-02-2009 |
| 20090068744 | VITREOUS CELL LINE - The present invention provides a vitreous cell line capable of expressing an exogenous immortalizing gene, and a production method thereof. Since the vitreous cell line of the present invention can produce a sufficient number of cells and has constant and continuous proliferative capacity, it can be advantageously utilized for the elucidation of the pathogenesis of retinal vitreous diseases, and the development of a drug for the prophylaxis and/or treatment of retinal vitreous diseases. Moreover, the cell line is not only highly useful for the biochemical-physiological studies of the vitreous body, and further for the study of cell differentiation mechanisms, but also possibly usable as a biological material of an artificial vitreous body. | 03-12-2009 |
| 20090053812 | SCLERAL CELL STRAIN - The present invention provides a scleral cell strain capable of expressing an exogenous immortalizing gene, and a production method thereof. Since the scleral cell strain of the present invention can produce a sufficient number of cells and has constant and continuous proliferative capacity, it can be advantageously utilized for the elucidation of the pathogenesis of ophthalmic diseases such as scleral inflammation, and the development of a drug for the prophylaxis and/or treatment of said diseases. Moreover, the cell strain is not only highly useful for the biochemical-physiological studies of the sclera, and further for the study of cell differentiation mechanisms, but also possibly usable as a biological material of an artificial sclera. | 02-26-2009 |
